Results 151 to 160 of about 1,052,643 (288)

Apremilast Use in Severe Psoriasis: Real-World Data from Central and Eastern Europe. [PDF]

Adv Ther, 2023
Cetkovská P, Dediol I, Šola M, Kojanová M, Trčko K, Čarija A, Čeović R, Ledić-Drvar D, Kaštelan M, Hrabar A, Missoup MC, Mamun K.   +11 more
europepmc   +1 more source

Central and Eastern Europe [PDF]

, 2011
openaire   +1 more source

Health sector reforms in Central and Eastern Europe [PDF]

The political and economic transition of the 1990s in the countries of central and eastern Europe has been accompanied by wide ranging health care reform. The initial Soviet model has given way to a variety of forms of health insurance.
FFF1Martin NNN1McKee, FFF2Ellen NNN2Nolte   +1 more
core  

Psychotropic medication use among community dwellers with and without Parkinson's disease – A nationwide cohort study

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aims We studied the prevalence of psychotropic use and psychotropic polypharmacy in persons with Parkinson's disease (PD) during a 10‐year follow‐up, because longitudinal studies on this topic are scarce although non‐motor symptoms of PD are often treated with psychotropics.
Noora Nieminen, Anna‐Maija Tolppanen, Valtteri Kaasinen, Marjaana Koponen, Sirpa Hartikainen   +4 more
wiley   +1 more source

Cervical cancer in Eastern Europe and Central Asia: the first signs of progress?

The Lancet Primary Care
Silvia Ussai, Teymur Seyidov, Nerea Blanqué Catalina, Tamar Khomasuridze   +3 more
doaj   +1 more source

Recommendations for wider adoption of clinical pharmacy in Central and Eastern Europe in order to optimise pharmacotherapy and improve patient outcomes. [PDF]

Front Pharmacol, 2023
Urbańczyk K, Guntschnig S, Antoniadis V, Falamic S, Kovacevic T, Kurczewska-Michalak M, Miljković B, Olearova A, Sviestina I, Szucs A, Tachkov K, Tiszai Z, Volmer D, Wiela-Hojeńska A, Fialova D, Vlcek J, Stuhec M, Hogg A, Scott M, Stewart D, Mair A, Ravera S, Lery FX, Kardas P.   +23 more
europepmc   +1 more source

Evaluating the (comparative) safety profile of the novel oral polio vaccine type 2 using individual case safety reports in VigiBase

British Journal of Clinical Pharmacology, EarlyView.
Aim Novel oral polio vaccine type 2 (nOPV2) was used under the WHO emergency use listing for circulating vaccine‐derived polio virus (cVDPV) outbreaks from 2021 to 2023. We assessed nOPV2 adverse events following immunization (AEFIs) and compared its safety profile to other vaccines using VigiBase.
Comfort Kunak Ogar, Malede Mequanent Sisay, Leonardo Roque‐Pereira, Christine Leopold, Patrick C. Souverein, Aukje K. Mantel‐Teeuwisse, Marie L. De Bruin   +6 more
wiley   +1 more source

Regional mortality disparities in Central and Eastern Europe 2000-22. [PDF]

J Public Health (Oxf)
Hrzic R, Grigoriev P.
europepmc   +1 more source

HIV Pre-Exposure Prophylaxis in Central and Eastern Europe-Gains and Challenges in An Ever-Changing World. [PDF]

Infect Dis Clin Microbiol, 2022
Gökengin D.
europepmc   +1 more source

Exchange Rate Regime and Wage Determination in Central and Eastern Europe [PDF]

After the eastern enlargement of the European Union due to increasing labor market integration, wage determination and monetary integration in Central and Eastern Europe have become key issues in European economic policy making. Based on the Scandinavian
Christina Ziegler, Gunther Schnabl
core